Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-06Clinical Trial Update: Intraoperative Brain Microdialysis to Assess Neuroinflammation in Epileptic Tissue Immediately Prior to Surgical Resection. [NA]
A Mayo Clinic-sponsored clinical trial evaluating intraoperative brain microdialysis to assess neuroinflammation in epileptic tissue before …
-
CLINICAL_TRIALS withdrawal · 2026-03-19Clinical Trial Update: Modulating Oscillations and Working Memory in Patients With Subdural Electrodes [NA]
A UNC Chapel Hill clinical trial evaluating modulation of brain oscillations to improve working memory in epilepsy patients with subdural el…
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Clinical Applications of High-Frequency Oscillations
A clinical trial investigating the clinical applications of high-frequency oscillations for epilepsy and migraine has been withdrawn.
-
EMA withdrawal · 2025-12-04EMA Application withdrawn: Tuzodi (Midazolam Hydrochloride) — Regulatory Pharma Net S.r.l.
The EMA has withdrawn the application for Tuzodi (Midazolam Hydrochloride) by Regulatory Pharma Net S.r.l., for seizures.
-
CLINICAL_TRIALS withdrawal · 2025-10-02Clinical Trial Update: Brain-Shift Monitoring Using 3D Scanning
A clinical trial evaluating brain-shift monitoring using 3D scanning has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-09-08Clinical Trial Update: EpiCare@Home Validation Study for Focal Onset Seizures [NA]
A clinical trial evaluating EpiCare@Home for focal onset seizures has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-29Clinical Trial Update: Impact of Pharmaceutical Interviews on the Medication Adherence of Epileptic Patients [NA]
A clinical trial evaluating whether pharmaceutical interviews improve medication adherence in epilepsy patients has been terminated.
-
EMA withdrawal · 2025-01-09EMA Application withdrawn: Epixram — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency has withdrawn the marketing authorization application for Epixram by Neuraxpharm Pharmaceuticals S.L., related…
-
CLINICAL_TRIALS withdrawal · 2024-12-30Clinical Trial Update: Efficacy of Intersectional Short Pulse Stimulation for Terminating Seizures [NA]
A clinical trial evaluating intersectional short pulse stimulation to terminate seizures has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-30Clinical Trial Update: Epilepsy Self-Management for Spanish Speakers: HOBSCOTCH - ESPANOL [NA]
The clinical trial HOBSCOTCH - ESPANOL for epilepsy self-management in Spanish speakers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-19Clinical Trial Update: Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase [NA]
The NEAM UG3 Phase trial evaluating neurodevelopmental effects of antiseizure medications has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-07-25Clinical Trial Update: Cardiovascular Risk Reduction in Epilepsy [NA]
A UCLA-sponsored clinical trial on cardiovascular risk reduction in epilepsy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-06-03Clinical Trial Update: Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies [Phase 2]
A Phase 2 study evaluating MGCND00EP1 as an add-on therapy for resistant epilepsy in children and adolescents has been withdrawn. No results…
-
EMA withdrawal · 2023-10-12EMA Withdrawn: Pregabalin Sandoz GmbH (pregabalin) — Sandoz GmbH
The EMA withdrew the Pregabalin Sandoz GmbH (pregabalin) product from the market, affecting indications in Anxiety Disorders and Epilepsy.
-
EMA withdrawal · 2023-03-20EMA Withdrawn: Pregabalin Zentiva k.s. (pregabalin) — Zentiva k.s.
The EMA withdrew pregabalin Zentiva k.s. from the market (Zentiva k.s.) with the therapeutic areas including anxiety disorders, neuralgia, a…
-
CLINICAL_TRIALS withdrawal · 2023-02-02Clinical Trial Update: Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline [Phase 4]
Phase 4 trial comparing pregabalin to sertraline for anxiety in epilepsy patients was withdrawn.
-
EMA withdrawal · 2022-04-26EMA Withdrawn: Pregabalin Mylan Pharma (pregabalin) — Mylan S.A.S.
EMA withdrawal notice for pregabalin marketed by Mylan S.A.S., affecting anxiety disorders, neuralgia, and epilepsy indications.
-
CLINICAL_TRIALS withdrawal · 2021-05-21Clinical Trial Update: Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus [Phase 2, Phase 3]
Clinical trial investigating ketamine infusion vs traditional anti-epileptic agents in refractory status epilepticus was withdrawn from phas…
-
EMA withdrawal · 2018-11-19EMA Withdrawn: Trobalt (retigabine) — Glaxo Group Limited
The EMA has withdrawn Trobalt (retigabine) from the market.
-
CLINICAL_TRIALS withdrawal · 2018-04-30Clinical Trial Update: Turmeric as Treatment in Epilepsy [NA]
A clinical trial evaluating turmeric as a treatment for epilepsy has been withdrawn, including conditions such as Dravet syndrome, Lennox-Ga…
-
CLINICAL_TRIALS withdrawal · 2018-03-15Clinical Trial Update: Transcranial Stimulation During Sleep to Improve Cognition in Epilepsy [NA]
A clinical trial evaluating transcranial stimulation during sleep to improve cognition in epilepsy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-01-16Clinical Trial Update: A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug [Phase 3]
A pediatric Phase 3 trial investigating long-term safety and tolerability of a drug for epilepsy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-11-28Clinical Trial Update: EEG@HOME (Phase 4 of the Project) [NA]
The EEG@HOME trial in epilepsy has been withdrawn; no further activity is planned.
-
CLINICAL_TRIALS withdrawal · 2017-08-29Clinical Trial Update: Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus [Phase 3]
Phase 3 trial evaluating adjunctive levetiracetam, lacosamide, and ketamine for refractory status epilepticus has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-18Clinical Trial Update: Computerized Cognitive Training in Epilepsy [NA]
The NYU Langone Health-sponsored trial evaluating computerized cognitive training for epilepsy has been withdrawn.